Revenues (USD, millions)

Cost of Products Sold (USD, millions)

Selling and Administrative Expense (USD, millions)

Research and Development Expense (USD, millions)

Integration, Restructuring and Transaction Expense (USD, millions)

Other Operating Expense, Net (USD, millions)

Integration and Restructuring Expense (USD, millions)

Other Operating (Income) Expense, Net (USD, millions)

Total Operating Costs and Expenses (USD, millions)

Operating Income (USD, millions)

Interest Expense (USD, millions)

Interest Income (USD, millions)

Other Expense, Net (USD, millions)

Other (Expense) Income, Net (USD, millions)

Income Before Income Taxes (USD, millions)

Income Tax Provision (USD, millions)

Net Income (USD, millions)

Preferred Stock Dividends (USD, millions)

Net Income Applicable to Common Shareholders (USD, millions)

Basic Earnings per Share (USD)

Diluted Earnings per Share (USD)

(Loss) Income from Discontinued Operations, Net of Tax (USD, millions)

Basic Earnings per Share - Income from Continuing Operations (USD)

Diluted Earnings per Share - Income from Continuing Operations (USD)

Dividends per Common Share (USD)

Basic Earnings per Share - (Loss) Income from Discontinued Operations (USD)

Diluted Earnings per Share - (Loss) Income from Discontinued Operations (USD)

991ded49f3b157e61dcdfbc5bfa6758a15df0e6d0d12b7e17bde3fe6b0db37cd

Net income (USD, millions)

Less: Income from discontinued operations, net of tax (USD, millions)

Income from continuing operations, net of tax (USD, millions)

Depreciation and amortization (USD, millions)

Share-based compensation (USD, millions)

Deferred income taxes (USD, millions)

Change in operating assets and liabilities (USD, millions)

Pension obligation (USD, millions)

Other, net - Operating Activities (USD, millions)

Net Cash Provided by Continuing Operating Activities (USD, millions)

Capital expenditures (USD, millions)

Acquisitions, net of cash acquired (USD, millions)

Other, net - Investing Activities (USD, millions)

Net Cash Used for Continuing Investing Activities (USD, millions)

Change in short-term debt (USD, millions)

Payments of debt (USD, millions)

Dividends paid (USD, millions)

Other, net - Financing Activities (USD, millions)

Net Cash Used for Continuing Financing Activities (USD, millions)

Net cash provided by operating activities - Discontinued Operations (USD, millions)

Net cash used for investing activities - Discontinued Operations (USD, millions)

Net Cash Provided by Discontinued Operations (USD, millions)

Effect of exchange rate changes on cash and equivalents and restricted cash (USD, millions)

Net decrease in cash and equivalents and restricted cash (USD, millions)

Proceeds from long-term debt (USD, millions)

Distribution from Embecta Corp. (see Note 2) (USD, millions)

Net transfer of cash to Embecta upon spin-off (USD, millions)

Repurchase of common stock (USD, millions)

Product liability-related charges (USD, millions)

Excess tax benefits from payments under share-based compensation plans (USD, millions)

Opening Cash and Equivalents and Restricted Cash (USD, millions)

Closing Cash and Equivalents and Restricted Cash (USD, millions)

5503fd6bc311023fda8fb0d2521ea7e084f1c37cc53fb23bc2334e4fdd2f4863

The spike in Cash and Cash Equivalents in Q3 2024 was primarily driven by **significant proceeds from long-term debt issuance** (amounting to **$4,517 million**) and **strong operating cash flows** (with **$2,666 million** generated from continuing operations), which were further bolstered by additional liquidity from the **factoring of trade receivables** (worth **$1,115 million**). These factors outweighed the cash used for investing and financing activities, leading to the overall increase in cash levels.  **[0000010795-24-000067_bdx-20240630.htm:21]** **[20240801NY74029:15]** **[0000010795-24-000064_ex99106302024.htm:10]** 

Why did Cash and Cash Equivalents spike in Q3 2024?

The **total assets** reached **$57,286 million** in Q4 2024 due to several factors, including an **increase in goodwill** from **$24,522 million** in 2023 to **$26,465 million** in 2024, higher **trade receivables** (rising from **$2,534 million** to **$3,033 million**), increased **inventories** (from **$3,273 million** to **$3,843 million**), improved **cash and equivalents** (from **$1,416 million** to **$1,717 million**), and a significant rise in **short-term investments** (from **$8 million** to **$445 million**). These changes collectively contributed to the overall increase in total assets in Q4 2024.  **[20241107NY49057:0]** **[0000010795-24-000084_bdx-20240930.htm:95]** 

Why did Total Assets reach 57,286 in Q4 2024?

The increase in long-term debt in Q3 2024 was primarily driven by **proceeds from long-term debt issuance of $4,517 million** and was partially offset by **debt payments of $1,142 million**. Additionally, the company undertook strategic financing for the **$4.2 billion acquisition of Edwards Lifesciences' Critical Care Product Group**, which further contributed to the rise in debt.  **[0000010795-24-000067_bdx-20240630.htm:3]** **[0000010795-24-000064_ex99106302024.htm:0]** **[20240801NY74029:0]** 

What caused the increase in Long-Term Debt in Q3 2024?

The documents show that Becton, Dickinson and Company reported **$2,016 million** in current debt obligations for Q2 2024  **[0000010795-24-000039_bdx-20240331.htm:3]**  and **$1,192 million** for Q3 2024.  **[0000010795-24-000067_bdx-20240630.htm:3]**  Although this represents a significant drop, the documents do not provide specific reasons for the decline. It is possible that the reduction resulted from routine debt management activities such as repayments or refinancing, but no definitive explanation is provided in the available information.  **[0000010795-24-000067_bdx-20240630.htm:3]** 

Why did Current Debt Obligations drop in Q3 2024?

ca30c746b700d50318299a28a0ee6164ec1d6e8b45fade975a36ce03cfe00758

Cash and equivalents (USD, millions)

Restricted cash (USD, millions)

Short-term investments (USD, millions)

Trade receivables, net (USD, millions)

Inventories (USD, millions)

Prepaid expenses and other (USD, millions)

Total Current Assets (USD, millions)

Property, Plant and Equipment, Net (USD, millions)

Other Assets (USD, millions)

Total Assets (USD, millions)

Current debt obligations (USD, millions)

Payables, accrued expenses and other current liabilities (USD, millions)

Long-Term Debt (USD, millions)

Long-Term Employee Benefit Obligations (USD, millions)

Deferred Income Taxes and Other Liabilities (USD, millions)

Total Shareholders’ Equity (USD, millions)

Total Liabilities and Shareholders’ Equity (USD, millions)

1d0cbdc096b6dc1eaa397efad165355273e17eaf8929346fe1c8fb81723829bb

Adjustments for Non-Cash Items [USD, Millions]

Stock-Based Compensation [USD, Millions]

Changes in Working Capital [USD, Millions]

Capital Expenditures (CapEx) [USD, Millions]

Proceeds from Debt [USD, Millions]

Repayments of Debt [USD, Millions]

Share Repurchases [USD, Millions]

Dividend Payments [USD, Millions]

Net Change in Cash [USD, Millions]

9d1b0c1af8367b8166d03dbbff96cd76de6c4f8a13c77519d1254dcdd170c80b

Total Revenue [USD, Millions]

Cost of Goods Sold (COGS) [USD, Millions]

Selling, General, and Administrative Expenses (SG&A) [USD, Millions]

Research and Development (R&D) [USD, Millions]

Depreciation and Amortization (D&A) [USD, Millions]

Interest Expense [USD, Millions]

Operating Income (EBIT) [USD, Millions]

Net Income [USD, Millions]

Earnings Per Share (EPS) - Basic [USD]

Earnings Per Share (EPS) - Diluted [USD]

cfe0eefd133e8a7d9c5d3777f9ee7c20bdb21db56057370531179ac31c0f28b1

c4f74fd524d33e1bb7137f711b2ddc043f7334d72e3e456e23bc54dd63d02ab3

6d2bcd263d04b239967b53ae682d5ab27655278ecf1a92d403663c826e7d84d8

United States

International

- Emerging Markets

EMEA (Europe, Middle East, Africa)

Greater Asia

Other (Latin America and Canada)

Total Revenue

691b58b056e37550aaf3ac04d9dbfa69ecab197facb4512028b2ba1e0eafa80b

622f63147164bb5e0220e971eae9ae79f0aa7e644c3648e8ce9caed3b0edeb4e

BECTON DICKINSON & (BDX)

Financials